

**Figure 1**  
**Clone C35**

**A. DNA Coding Sequence**

gcc gcg ATG AGC GGG GAG CCG GGG CAG ACG TCC GTA  
GCG CCC CCT CCC GAG GAG GTC GAG CCG GGC AGT  
GGG GTC CGC ATC GTG GTG GAG TAC TGT GAA CCC  
TGC GGC TTC GAG GCG ACC TAC CTG GAG CTG GCC  
AGT GCT GTG AAG GAG CAG TAT CCG GGC ATC GAG  
ATC GAG TCG CGC CTC GGG GGC ACA GGT GCC TTT  
GAG ATA GAG ATA AAT GGA CAG CTG GTG TTC TCC  
AAG CTG GAG AAT GGG GGC TTT CCC TAT GAG AAA  
GAT CTC ATT GAG GCC ATC CGA AGA GCC AGT AAT  
GGA GAA ACC CTA GAA AAG ATC ACC AAC AGC CGT  
CCT CCC TGC GTC ATC CTG TGA

**B. Protein Sequence**

MSGEPGQTSVAPPPEEVEPGSGVRIVVEYCEPCGFEATYLEL  
ASAVKEQYPGIEIESRLGGTGAFIEINGQLVFSKLENGGFY  
EKDLIEAIRRASNGETLEKITNSRPPCVIL\*

Figure 2. C35 is Expressed at High Levels in Breast Tumors but Not Normal Tissues






Figure 3




# Figure 4

A.




2INT PMT2  
2INT C36 A PMT2

B.



SKBR3 NS PMT2  
SKBR3 C36 PMT2

C.



MDA PMT2  
MDA C36 LM PMT2

Figure 5A




Figure 5B  
Percent Specific Lysis  
Effector : Target

<u>Target</u>	<u>10:1</u>	<u>2:1</u>
BCA 34	68.4	54.8
BCA 39	36.6	23.4
B/C.N	0.2	0.3
B/C.N + vF5.8	47.5	34.6
B/C.N + vH2.16	67.8	56.2
B/C.N + vaccinia vector	0	0.2

Figure 6

A. L3

Amino Acid Position	45	46	47	48	49	50	51	52	53	54	55	56
Sequence	A	F	L	G	Y	K	A	G	M	T	H	I
Nucleotide	GCC	TTT	CTG	GGT	TAC	AAG	GCT	GGC	ATG	ACC	CAC	ATC

B. H2.16

Amino Acid Position	45	46	47	48	49	50	51	52	53	54	55	56
Sequence	A	F	L	G	Y	K	A	G	M	I	H	I
Nucleotide	-	-	-	-	-	-	-	-	-	-T-	-	-

Figure 7A  
Percent Specific Lysis  
Effector: Target

<u>Target</u>	<u>10:1</u>	<u>2:1</u>
BCA 34	62.4	32.1
BCA 39	49.7	23.6
B/C.N	3.3	0.2
B/C.N + L3 peptide 48-56(I54)	46.0	16.1
B/C.N + L3 peptide 48-56(T54)	2.0	0
B/C.N + L3 peptide 45-54(I54)	0	0

Figure 7B






Figure 8A

Published L3 (1276 bp)



168-171 = GACC

H2.16 (1276 bp)



168-171 = GATC

Figure 8B




Figure 8C




Figure 9A

<u>Target</u>	Percent Specific Lysis			
	vH2.16		v7.5/tk	
	<u>40:1</u>	<u>10:1</u>	<u>40:1</u>	<u>10:1</u>
BCA 34	33.6	12.9	5.7	4.0
BCA 39	22.1	9.0	5.3	3.1
B/C.N + L3 48-56 (I54)	48.2	20.2	3.9	1.5
B/C.N + L3 48-56 (T54)	6.4	1.4	1.8	2.9
B/C.N	7.1	5.7	6.1	2.8
YAC	1.2	2.5	0	1.8






Figure 9C



### A.


gccccgagcggagccggccgcg ATG AGC GGG GAG CCG GGG CAG ACG TCC  
M S G E P G Q T S  
GTA GCG CCC CCT CCC GAG GAG GTC GAG CCG GGC AGT GGG GTC CGC  
V A P P E E V E P G S G V R  
ATC GTG GTG GAG TAC TGT GAA CCC TGC GGC TTC GAG GCG ACC TAC  
I V V E Y C E P C G F E A T Y  
CTG GAG CTG GCC AGT GCT GTG AAG GAG CAG TAT CCG GGC ATC GAG  
L E L A S A V K E Q Y P G I E  
ATC GAG TCG CGC CTC GGG GGC ACA GGT GCC TTT GAG ATA GAG ATA  
I E S R L G G T G A F E I E I  
AAT GGA CAG CTG GTG TTC TCC AAG CTG GAG AAT GGG GGC TTT CCC  
N G Q L V F S K L E N G G F P  
TAT GAG AAA GAT CTC ATT GAG GCC ATC CGA AGA GCC AGT AAT GGA  
Y E K D L I E A I R R A S N G  
GAA ACC CTA GAA AAG ATC ACC AAC AGC CGT CCT CCC TGC GTC ATC  
E T L E K I T N S R P P [C V I]  
CTG TGA ctgcacaggactctgggttcctgctctgttctgggtccaaaccttggct  
L \*  
ccctttggtcctgctggagctccccctgcctcttcccacttagtccttagaaaa  
gagaccctggcctccactttgcccttgggtacaaaagaaggaatagaagattccgtggc  
cttggggcaggagagagacactctccatgaacacttctccagccacctctatccccctt  
cccagggttaagtgcacgaaagcccactccactttcgctcgtaataacctgtctga  
tgccacagatttatttattctcccctaaccaggcaatgtcagctatggcagtaaaa  
gtggcgctac-polyA

### B.




**Figure 10**

### A. Breast epithelial cell lines




### B. Primary breast tissue/tumors




**Figure 11**

## Primary bladder tumors




**Figure 12**

### **A. BREAST**




### **B. BLADDER**




**Figure 13**

21NT Breast Tumor




H16N2 Normal Breast




**Figure 14**

**A. Lytic activity of C35-specific T cell line 4**




**B. Lytic activity of C35-specific T cell clone 10G3**



**Figure 15**

A.



B.





Figure 16

## Tolerance to Alloantigens Induced in presence of Antigens and Anti-CD40 Ligand Antibody



**Figure 17**